Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00407381 · ClinicalTrials.gov registry record · Phase 2
The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT00407381: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00407381 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 126 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00407381, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
This study is being done to see if the investigational drug Ranibizumab (RBZ) given by injection into the eye, is safe and effective to use in people with diabetic macular edema (DME). The investigators want to compare RBZ to laser treatment which is the current standard way to treat DME. RBZ blocks a growth factor that is thought to be involved in the formation of abnormal blood vessels that cause loss of vision in patients with DME.
Interventions
- DRUG Ranibizumab
- PROCEDURE Laser photocoagulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00407381
The ClinicalTrials.gov registry entry for NCT00407381 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ranibizumab is the first listed.
NCT00407381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00407381 about?
NCT00407381 is a clinical study titled "The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study". This study is being done to see if the investigational drug Ranibizumab (RBZ) given by injection into the eye, is safe and effective to use in people with diabetic macular edema (DME). The investigators want to compare RBZ to laser treatment which is the current standard way to treat DME. RBZ block...
What is the current status of trial NCT00407381?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2006-12. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00407381?
The interventions under investigation include: Ranibizumab (DRUG), Laser photocoagulation (PROCEDURE).
Who is sponsoring clinical trial NCT00407381?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.